News

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...
Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...
What is Japanese Potato Salad? Potato salad might not be the first thing that comes to mind when you think of Japanese ...
Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...
Old Forester is celebrating in style with its 2025 Birthday Bourbon, and we were lucky enough to get a firsthand taste of ...
Shares of Novo Nordisk (NYSE: NVO), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped ...
Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.
Old Forester is shaking things up with its 25th Birthday Bourbon release, swapping its usual sour mash process for sweet mash ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...
The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
Novo Nordisk shares (DK:NOVO.B) (NVO) rose 5% in opening New York trade. The American depository receipts however have plunged 37% this year amid increased competition for its weight-loss drugs as ...